Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18178662 | 0.93 | MRGPRX4 (0.37) | MAPTMRGPRX4ACHEAKR1C3NR1H4 | |
| SCHEMBL18178663 | 0.93 | SLC22A12 (0.39) | MAPTMRGPRX4ACHEAKR1C3NR1H4 | |
| SCHEMBL18530975 | 0.93 | MAPT (0.40) | MAPTMRGPRX4ACHEAKR1C3NR1H4 | |
| SCHEMBL18178654 | 0.93 | MAPT (0.38) | MAPTMRGPRX4ACHEAKR1C3NR1H4 | |
| SCHEMBL18530989 | 0.91 | MAPT (0.36) | MAPTMRGPRX4ACHEAKR1C3ALDH1A1 | |
| SCHEMBL18530972 | 0.91 | MRGPRX4 (0.38) | MAPTMRGPRX4ACHEALDH1A1 | |
| SCHEMBL18530983 | 0.91 | LMNA (0.36) | MAPTMRGPRX4ACHELMNA | |
| SCHEMBL18178725 | 0.91 | ACHE (0.39) | MAPTMRGPRX4ACHEALDH1A1SLC22A12 | |
| SCHEMBL18178642 | 0.90 | MAPT (0.36) | MAPTMRGPRX4ACHEALDH1A1LMNA | |
| SCHEMBL18178669 | 0.90 | ACHE (0.34) | MAPTMRGPRX4ACHEAKR1C3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | MAPT 4572/4885MRGPRX4 167/4885ACHE 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.